roche investor update r basel 10 october 2002 s pharmaceuticals and diagnostics divisions on course download pdf english nine month sales in core businesses up 7 local currencies division posts 6 growth prescription drug show double digit gains us japan 11 pegasys launched eu review of nda moving ahead schedule marketing applications for fuzeon filed advance at rate preparations to sell vitamins forward as planned integration chugai off a successful start largest company with foreign majority shareholder vitamin case provisions increased by 1 2 billion swiss francs reaffirms guidance current year anticipates increases consolidated operating profit ebitda margins expects from 2003 the group recorded 21 first months combined revenues totalled 19 3 equivalent
